Results 1 to 10 of about 5,627 (198)
Preclinical Studies of Granulysin-Based Anti-MUC1-Tn Immunotoxins as a New Antitumoral Treatment [PDF]
Two granulysin (GRNLY) based immunotoxins were generated, one containing the scFv of the SM3 mAb (SM3GRNLY) and the other the scFv of the AR20.5 mAb (AR20.5GRNLY). These mAb recognize different amino acid sequences of aberrantly O-glycosylated MUC1, also
Francisco Corzana +2 more
exaly +4 more sources
Comparison of two immunotoxins against DLL3 receptor; as an inhibitor for small cell lung cancer [PDF]
Despite the efforts of researchers to develop new treatments for small cell lung cancer (SCLC), achieving effective treatment has not yet happened. Targeted therapy utilizing delta-like ligand 3 (DLL3), which is highly expressed in SCLC patients, holds ...
Mohammad Hossein Ataee +4 more
doaj +4 more sources
Immunotoxins: From Design to Clinical Application
The Special Issue of Biomolecules entitled “Immunotoxins, From Design to Clinical Application” contains seven reviews related to immunotoxins [...]
Robert J. Kreitman, Ira Pastan
doaj +2 more sources
Immunotoxins Immunotherapy against Hepatocellular Carcinoma: A Promising Prospect
Hepatocellular carcinoma (HCC) is one of the most common cancers in the world. Therefore, fighting against such cancer is reasonable. Chemotherapy drugs are sometimes inefficient and often accompanied by undesirable side effects for patients.
Mohammad Heiat +3 more
doaj +2 more sources
Immunotoxins are cytolytic fusion proteins developed for cancer therapy, composed of an antibody fragment that binds to a cancer cell and a protein toxin fragment that kills the cell.
Ronit Mazor, Ira Pastan
exaly +3 more sources
The Use of Bacteria and Their Toxins as Antitumor Agents: Present and Future [PDF]
Cancer remains one of the leading causes of morbidity and mortality worldwide, and despite major advances in surgery, chemotherapy, radiotherapy, and immunotherapy, important therapeutic limitations persist, including systemic toxicity, therapeutic ...
Luz María Ibarra-Velázquez +5 more
doaj +2 more sources
Comparative Efficacy of Ribosome-Inactivating Protein-Containing Immunotoxins in 2D and 3D Models of Sarcoma [PDF]
Sarcomas are very complex and clinically challenging mesenchymal tumors. Although the standard therapeutic approach has improved the 5-year survival rate, many patients experience local relapses and/or distant metastases.
Giulia Calafato +3 more
doaj +2 more sources
Background and purpose: The lack of a new effective treatment for small cell lung cancer (SCLC) is an unresolved problem. Due to the new identification of delta-like ligand 3 (DLL3) and its high expression in SCLC patients, the use of DLL3 in target ...
Mohammad Hossein Ataee +5 more
doaj +1 more source
Recombinant immunotoxins development for HER2-based targeted cancer therapies
Understanding the molecular mechanisms of cancer biology introduces targeted therapy as a complementary method along with other conventional therapies. Recombinant immunotoxins are tumor specific antibodies that their recognizing fragment is utilized for
Reza Mahmoudi +6 more
doaj +1 more source
Immunotoxins: Targeted Toxin Delivery for Cancer Therapy
Immunotoxins are proteins that consist of a protein toxin conjugated to a specific targeting moiety. The targeting moiety is usually an antibody or ligand, such as monoclonal antibody, antibody fragment, a cytokine, or a growth factor. The toxins usually
Xin Mei +3 more
doaj +1 more source

